- Trials with a EudraCT protocol (131)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
131 result(s) found for: Programmed Cell Death.
Displaying page 1 of 7.
EudraCT Number: 2016-001688-35 | Sponsor Protocol Number: APACHE | Start Date*: 2016-09-09 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, alone or in combination with Tremelimumab, in patients with advanced and relapsed germ cell tumors | |||||||||||||
Medical condition: Advanced and relapsed germ cell tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001089-33 | Sponsor Protocol Number: 2007-001089-33 | Start Date*: 2008-09-23 | |||||||||||||||||||||
Sponsor Name:University Medical Center Groningen, dept. of Cardiology [...] | |||||||||||||||||||||||
Full Title: Infusion of a single dose of erythropoietin to Prevent Injury in an Ischemia Reperfusion forearm model - A randomised cross-over study to evaluate if infusion of a single dose of EPO protects again... | |||||||||||||||||||||||
Medical condition: Myocardial ischemia-reperfusion injury. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003616-31 | Sponsor Protocol Number: MK-7339-013 | Start Date*: 2020-10-19 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-... | |||||||||||||
Medical condition: Limited-Stage Small Cell Lung Cancer (LS-SCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Ongoing) FR (Ongoing) LT (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) IT (Ongoing) BG (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005115-32 | Sponsor Protocol Number: 213824 | Start Date*: 2022-09-16 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Phase 2, Randomized, Open-label Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated Locally Advanced/Metastatic Prog... | |||||||||||||
Medical condition: Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Ongoing) ES (Ongoing) NL (Ongoing) BE (Ongoing) DE (Ongoing) IT (Ongoing) PL (Ongoing) PT (Ongoing) HU (Ongoing) GR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003152-37 | Sponsor Protocol Number: MK3475-A18/ENGOT-cx11/GOG-3047 | Start Date*: 2020-05-28 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc | |||||||||||||
Full Title: A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047) | |||||||||||||
Medical condition: High-risk locally advanced cervical cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NO (Ongoing) HU (Ongoing) CZ (Ongoing) ES (Ongoing) FR (Ongoing) IE (Ongoing) SE (Ongoing) DE (Ongoing) GR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001971-61 | Sponsor Protocol Number: SALYCENDO | Start Date*: 2016-08-29 |
Sponsor Name:Radboudumc | ||
Full Title: The effects of acetylsalicylic acid on immunoparalysis following human endotoxemia. | ||
Medical condition: We will investigate the effects of acetylsalicylic acid on immunoparalysis following human endotoxemia in healthy male volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002105-99 | Sponsor Protocol Number: ACT16903 | Start Date*: 2022-01-20 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Développement | |||||||||||||
Full Title: A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participa... | |||||||||||||
Medical condition: Squamous cell carcinoma of head and neck | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002846-61 | Sponsor Protocol Number: ACT15319 | Start Date*: 2018-04-10 | ||||||||||||||||
Sponsor Name:Sanofi-aventis recherche & développement | ||||||||||||||||||
Full Title: A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination with REGN2810, or Isatuximab alone, in Patients with Advan... | ||||||||||||||||||
Medical condition: - Prostate cancer - Non-small cell lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004773-29 | Sponsor Protocol Number: GO41854 | Start Date*: 2020-08-31 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT... | |||||||||||||
Medical condition: Non−small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) BE (Ongoing) AT (Ongoing) PL (Ongoing) HU (Ongoing) NL (Ongoing) GR (Ongoing) FR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001270-34 | Sponsor Protocol Number: RIMAL1 | Start Date*: 2021-04-19 | |||||||||||
Sponsor Name:Radboud University Medical Centre | |||||||||||||
Full Title: Enhancement of immune response by combining immune checkpoint blockade and radiation in patients with recurrent / refractory malignant lymphoma (re-directing the immune system). | |||||||||||||
Medical condition: patients with recurrent / refractory 9p24.1 amplified malignant lymphomas patients with recurrent / refractory malignant lymphoma without 9p24.1 amplification | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002695-40 | Sponsor Protocol Number: MO43156 | Start Date*: 2021-12-28 | |||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE II, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER PLATINUM-BASED CONCURRENT CHEMORADIAT... | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) SI (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002638-18 | Sponsor Protocol Number: 20190288 | Start Date*: 2021-10-14 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment | |||||||||||||
Medical condition: KRAS p.G12C mutant untreated stage IV Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) ES (Prematurely Ended) DE (Temporarily Halted) BE (Completed) NL (Ongoing) SE (Prematurely Ended) DK (Prematurely Ended) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003636-79 | Sponsor Protocol Number: 18-214-10/CA045-012 | Start Date*: 2019-09-02 | |||||||||||
Sponsor Name:Nektar Therapeutics | |||||||||||||
Full Title: A Phase 2, single-arm study of bempegaldesleukin (NKTR-214) in combination with nivolumab in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients | |||||||||||||
Medical condition: Locally advanced or metastatic urothelial bladder cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) NL (Completed) DK (Completed) FI (Completed) DE (Completed) PL (Completed) GR (Completed) BE (Completed) AT (Completed) ES (Prematurely Ended) FR (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002474-39 | Sponsor Protocol Number: VBN-01 | Start Date*: 2018-01-17 | |||||||||||||||||||||||||||||||
Sponsor Name:Nykode Therapeutics AS | |||||||||||||||||||||||||||||||||
Full Title: An open-label first-in-human phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO or VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy... | |||||||||||||||||||||||||||||||||
Medical condition: Locally advanced or metastatic solid tumours including melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or SCCHN | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002263-99 | Sponsor Protocol Number: 209229 | Start Date*: 2020-05-12 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squ... | |||||||||||||
Medical condition: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) IE (Completed) SE (Completed) DE (Prematurely Ended) PL (Completed) DK (Completed) AT (Prematurely Ended) NO (Completed) HU (Prematurely Ended) GR (Ongoing) PT (Ongoing) ES (Temporarily Halted) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005192-39 | Sponsor Protocol Number: 202100663 | Start Date*: 2022-04-11 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell lymphoma who are treated with CD19-directed CAR T-cell therapy | ||
Medical condition: Patients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of therapy who fulfill the eligibility criteria for CD19-directed CAR T-cell therapy according the Immune Effe... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004502-93 | Sponsor Protocol Number: CA209-026 | Start Date*: 2014-04-23 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer | ||||||||||||||||||
Medical condition: Stage IV or Recurrent Non-Small Cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) DE (Completed) BE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) SE (Completed) FI (Completed) CZ (Completed) HU (Completed) IT (Completed) FR (Completed) NL (Completed) RO (Ongoing) PL (Completed) GR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003330-32 | Sponsor Protocol Number: GO28754 | Start Date*: 2014-04-17 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH PD L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | |||||||||||||
Medical condition: PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SI (Completed) IT (Completed) BE (Completed) DE (Completed) GB (Completed) NL (Completed) FR (Completed) ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003479-78 | Sponsor Protocol Number: SGN22E-001 | Start Date*: 2018-08-29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Seattle Genetics Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoin... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with locally advanced or metastatic urothelial cancer. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) NL (Completed) IT (Restarted) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001034-14 | Sponsor Protocol Number: 07/Q0803/31 | Start Date*: 2007-08-10 | ||||||||||||||||
Sponsor Name:St George's Healthcare NHS Trust [...] | ||||||||||||||||||
Full Title: The effect of omega-3 fatty acids on Barrett's oesophagus | ||||||||||||||||||
Medical condition: Barrett's oesophagus refers to changes in the lining of the lower oesophagus in response to injury caused by gastric reflux. It is a pre-malignant condition and has a well established link with ad... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.